MDMA治疗成人PTSD。

Q3 Medicine Psychopharmacology bulletin Pub Date : 2021-06-01
Dustin Latimer, Michael D Stocker, Kia Sayers, Jackson Green, Adam M Kaye, Alaa Abd-Elsayed, Elyse M Cornett, Alan D Kaye, Giustino Varrassi, Omar Viswanath, Ivan Urits
{"title":"MDMA治疗成人PTSD。","authors":"Dustin Latimer,&nbsp;Michael D Stocker,&nbsp;Kia Sayers,&nbsp;Jackson Green,&nbsp;Adam M Kaye,&nbsp;Alaa Abd-Elsayed,&nbsp;Elyse M Cornett,&nbsp;Alan D Kaye,&nbsp;Giustino Varrassi,&nbsp;Omar Viswanath,&nbsp;Ivan Urits","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Post-traumatic stress disorder (PTSD) has become one of the most common psychiatric diagnosis in the United States specifically within the veteran population. The current treatment options for this debilitating diagnosis include trauma-focused psychotherapies along with selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI).<sup>1</sup> MDMA has recently been shown as a novel therapeutic agent with promisingly results in the treatment of PTSD. MDMA is a psychoactive compound traditionally categorized as a psychedelic amphetamine that deemed a Schedule I controlled substance in the 1980s. Prior to its status as a controlled substance, it was used by psychotherapists for an array of psychiatric issues. In more recent times, MDMA has resurfaced as a potential therapy for PTSD and the data produced from randomized, controlled trials back the desire for MDMA to be utilized as an effective pharmacologic therapy in conjunction with psychotherapy.<sup>2</sup>.</p>","PeriodicalId":21069,"journal":{"name":"Psychopharmacology bulletin","volume":"51 3","pages":"125-149"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374929/pdf/PB-51-3-125.pdf","citationCount":"0","resultStr":"{\"title\":\"MDMA to Treat PTSD in Adults.\",\"authors\":\"Dustin Latimer,&nbsp;Michael D Stocker,&nbsp;Kia Sayers,&nbsp;Jackson Green,&nbsp;Adam M Kaye,&nbsp;Alaa Abd-Elsayed,&nbsp;Elyse M Cornett,&nbsp;Alan D Kaye,&nbsp;Giustino Varrassi,&nbsp;Omar Viswanath,&nbsp;Ivan Urits\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Post-traumatic stress disorder (PTSD) has become one of the most common psychiatric diagnosis in the United States specifically within the veteran population. The current treatment options for this debilitating diagnosis include trauma-focused psychotherapies along with selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI).<sup>1</sup> MDMA has recently been shown as a novel therapeutic agent with promisingly results in the treatment of PTSD. MDMA is a psychoactive compound traditionally categorized as a psychedelic amphetamine that deemed a Schedule I controlled substance in the 1980s. Prior to its status as a controlled substance, it was used by psychotherapists for an array of psychiatric issues. In more recent times, MDMA has resurfaced as a potential therapy for PTSD and the data produced from randomized, controlled trials back the desire for MDMA to be utilized as an effective pharmacologic therapy in conjunction with psychotherapy.<sup>2</sup>.</p>\",\"PeriodicalId\":21069,\"journal\":{\"name\":\"Psychopharmacology bulletin\",\"volume\":\"51 3\",\"pages\":\"125-149\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374929/pdf/PB-51-3-125.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

创伤后应激障碍(PTSD)已经成为美国最常见的精神病诊断之一,特别是在退伍军人人群中。目前对这种衰弱性诊断的治疗选择包括以创伤为重点的心理治疗以及选择性血清素再摄取抑制剂(SSRI)和血清素-去甲肾上腺素再摄取抑制剂(SNRI)MDMA最近被证明是一种新的治疗药物,在治疗创伤后应激障碍方面有很好的效果。MDMA是一种精神活性化合物,传统上被归类为迷幻药安非他明,在20世纪80年代被列为一级管制物质。在它被列为管制药物之前,它被心理治疗师用于治疗一系列精神问题。最近,MDMA作为一种潜在的治疗创伤后应激障碍的方法重新出现,随机对照试验的数据支持MDMA作为一种有效的药物治疗与心理治疗相结合的愿望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
MDMA to Treat PTSD in Adults.

Post-traumatic stress disorder (PTSD) has become one of the most common psychiatric diagnosis in the United States specifically within the veteran population. The current treatment options for this debilitating diagnosis include trauma-focused psychotherapies along with selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI).1 MDMA has recently been shown as a novel therapeutic agent with promisingly results in the treatment of PTSD. MDMA is a psychoactive compound traditionally categorized as a psychedelic amphetamine that deemed a Schedule I controlled substance in the 1980s. Prior to its status as a controlled substance, it was used by psychotherapists for an array of psychiatric issues. In more recent times, MDMA has resurfaced as a potential therapy for PTSD and the data produced from randomized, controlled trials back the desire for MDMA to be utilized as an effective pharmacologic therapy in conjunction with psychotherapy.2.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Psychopharmacology bulletin
Psychopharmacology bulletin PHARMACOLOGY & PHARMACY-PSYCHIATRY
CiteScore
2.70
自引率
0.00%
发文量
32
期刊介绍: Information not localized
期刊最新文献
Takotsubo Cardiomyopathy Related to Duloxetine-Atomoxetine Combination in an Adolescent with ADHD and Comorbid GAD. On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression. Alzheimer's and Dementia Guidelines and Tables. Captagone & Morbid Jealousy. Are Standardized Tests Sensitive to Early Cognitive Change in Parkinson's Disease?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1